Abstract
The journal apologises for an error in the footnote to table 3 of this article published in the November issue of the European Journal of Endocrinology (vol 167, iss 5, pp 651–662). In the footnote, the information relating to the clinical details of patients should read as:
aClinical details on patients 1 and 3 have been reported in references (40, 42) respectively. and not as published
References
40 Petrossians P, de Herder W, Kwekkeboom D, Lamberigts G, Stevenaert A & Beckers A. Malignant prolactinoma discovered by D2 receptor imaging. Journal of Clinical Endocrinology and Metabolism 2000 85 398–401. (doi:10.1210/jc.85.1.398)
42 Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F & Brue T. Temozolomide treatment in aggressive pituitary tumors and pituitarycarcinomas: a Frenchmulticenter experience. Journal of Clinical Endocrinology and Metabolism 2010 95 4592–4599. (doi:10.1210/jc.2010-0644)
